MSMEs have availed the benefit under erstwhile PTUAS scheme. However, the PTUAS has been incorporated as a sub-scheme under the Scheme – Strengthening of Pharmaceutical Industry (SPI), which was launched in July 2022.
The Strengthening of Pharmaceutical Industry (SPI), with the financial outlay of Rs. 500 crores and with a tenure from FY 2021-2022 to FY 2025-26, has following three components, to provide infrastructure support for pharma MSMEs in clusters and to address the issues of technology upgradation of individual pharma MSMEs :-
- Assistance to Pharmaceutical Industry for Common Facilities (API-CF)
- Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS
- Pharmaceutical & Medical Devices Promotion and Development Scheme (PMPDS)
The sub-scheme PTUAS is aimed to facilitate Micro, Small and Medium Pharma Enterprises (MSMEs) of proven track record to meet national and international regulatory standards (WHO-GMP or Schedule-M), interest subvention or capital subsidy on their capital loans will be provided, which will further facilitate the growth in volumes as well as in quality and it is ensivaged to support about 400 Pharma MSME units under this sub-scheme during the scheme tenure.
PTUAS is a credit linked scheme and under this, applications are invited from eligible Pharma MSME units since 01.08.2022. For registration of application, online portal has been developed by SIDBI, the Project Management Consultant (PMC) of the scheme and details are available at https://spi.udyamimitra.in. About 60 applications have been registered till date.
Further, one national and 10 State level outreach events were conducted, involving the State Governments and Pharma Industry Associations for maximum outreach and awareness for larger participation by Pharma MSME industries to avail the scheme benefits.
This information was given by Minister of State for Chemicals and Fertilizers, Shri Bhagwanth Khuba in a written reply in Rajya Sabha today.
Comments are closed.